Animal models of Alzheimer's disease have suggested that tau pathology propagation, facilitated by amyloid pathology, may occur along connected pathways. To investigate these ideas in humans, we combined amyloid scans with longitudinal data on white matter connectivity, hippocampal volume, tau positron emission tomography and memory performance in 256 cognitively healthy older individuals. Lower baseline hippocampal volume was associated with increased mean diffusivity of the connecting hippocampal cingulum bundle (HCB). HCB diffusivity predicted tau accumulation in the downstream-connected posterior cingulate cortex in amyloid-positive but not in amyloid-negative individuals. Furthermore, HCB diffusivity predicted memory decline in amyloid-positive individuals with high posterior cingulate cortex tau binding. Our results provide in vivo evidence that higher amyloid pathology strengthens the association between HCB diffusivity and tau accumulation in the downstream posterior cingulate cortex and facilitates memory decline. This confirms amyloid's crucial role in potentiating neural vulnerability and memory decline marking the onset of preclinical Alzheimer's disease.
A myloid-beta plaques and tau neurofibrillary tangles, the hallmark lesions of Alzheimer's disease (AD), progress in predictable topographical patterns 1 . Amyloid plaques accumulate first in neocortical areas and then in subcortical regions as the disease progresses. Tau neurofibrillary tangles are detected first in the entorhinal cortex, and after affecting other medial temporal regions, they spread to other limbic structures and finally to the neocortex 1, 2 . Cognitive functions, especially memory, gradually decline as pathology slowly progresses in load and extent, marking the insidious onset of AD.
Animal studies have provided evidence that the topographical patterns of tau pathology reflect spreading of tau via synaptic connectivity 3, 4 . The highest concentration of normally occurring tau protein is found in axons, the connections between cells. As axons do not have the required processes to render tau pathology in a fibrillar state, pathological tau remains in the axon for a long period of time, allowing these soluble aggregates of the misfolded protein to propagate via axons and cell-to-cell synaptic transmission [5] [6] [7] [8] [9] . It remains unclear whether in human disease tau propagation occurs mainly via direct cellular connectivity 3 or by a combination of connectivity and proximity (regional vulnerability) 5, 6, 10 . Notably, amyloid appears to potentiate the propagation of neurofibrillary tangles 4, 11 . Clarification of how tau pathology spreads and the role of amyloid deposition in this process will be key for understanding the pathophysiology of AD and defining new treatment targets.
Motivated by these previous findings, we sought to explore the overarching hypothesis that tau deposition is associated with aberrant structural connectivity under the influence of increased amyloidosis. Additionally, we explored the relevance of these associations for memory in a healthy older population. We combined the recently developed positron-emission tomography (PET) tracer flortaucipir (FTP), which binds specifically to tau pathology [12] [13] [14] , with established diffusion tensor imaging (DTI) methods 15, 16 , which measure fiber microstructural properties, and amyloid PET imaging 17 . These methods allowed us to model the untested hypothesis of propagation via connectivity or proximity in vivo in humans from an imaging perspective, assuming parallels to the biological mechanisms examined in animal studies, albeit on different resolution scales. To that end, we evaluated hypothesized associations ( Fig. 1) using longitudinal imaging and memory data from the Harvard Aging Brain Study (HABS), an ongoing study of cognitively healthy individuals (n = 256) followed for up to 7 years.
Rationale for investigating limbic pathways in our tau propagation model. Our design is motivated in part by the approach of a recent animal study investigating tau propagation via connectivity or proximity, showing that tau pathology in hippocampal neurons spreads to connected regions and affects the white matter tracts connecting the hippocampus with the distal region 3 . Figure 1 shows the hypothesized associations investigated consecutively in this study. Histological data suggests that early propagation of tau pathology occurs from the entorhinal cortex to the hippocampus, via the perforant pathway 2, 18 . As the perforant pathway cannot be captured with the current spatial resolution of DTI, we focused on a fiber tract strongly connected to the hippocampus to explore associations between hippocampal neurodegeneration and tract diffusivity 19 . Since the novel tau-tracer FTP was added to the study around year 3-4, we considered variations in hippocampal volume
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at baseline as a proxy for aging-associated hippocampal tau-related neurodegeneration 20 . The tract that can be measured most reliably and has the densest connections in the hippocampus is the hippocampal cingulum bundle (HCB) 21 . We predicted that hippocampal volume at baseline would predict abnormal HCB diffusivity over time ( Fig. 1) . Diffusivity of the HCB would in turn be associated with tau accumulation in the downstream-connected posterior cingulate cortex (PCC) and both processes would be associated with memory decline over a 6-year period. Recent cross-sectional work from our group suggested that the interaction between amyloid and tau occurs in posterior hippocampal and PCC regions 22 , supporting the selection of these regions. We additionally included the uncinate fasciculus (UF) as a control tract, since this tract innervates the medial temporal lobe but not the hippocampus 23 . Furthermore, the UF innervates the prefrontal lobe, a region with limited tau binding in cognitively healthy older individuals. For tau accumulation, we included inferior temporal (IT) tau load as a control measure for spread via proximity versus connectivity. The inferior temporal lobe is spatially proximate to the hippocampus and does not primarily have connections from the HCB. Finally, using this approach, we also investigated the potential moderating role of amyloid in tau propagation and memory decline. Previous postmortem studies have shown that tau pathology in the hippocampus is higher in amyloid-positive individuals compared to amyloid-negative individuals and that tau pathology outside of the medial temporal lobe in the context of amyloid pathology is associated with increased cognitive decline 24, 25 . We therefore hypothesized that neocortical amyloid deposition is associated with increased hippocampal volume loss and potentiates the effect of abnormal tract diffusivity on increased tau-accumulation in the PCC (Fig. 1 ).
Results
Participants (n = 256) from the HABS 26 underwent serial imaging and annual neuropsychological assessments over 7 years ( Supplementary Fig. 1 ). At baseline, the median age of the participants was 73.5 years (interquartile range (IQR): 68.5-78.25 years), their median educational level was 16 years (IQR: 13-18 years) and their median Mini-Mental State Examination (MMSE) screening score was 29 points (IQR: [28] [29] [30] . One hundred forty-five participants (60.16%) were female. At baseline, all participants were cognitively healthy as determined by the MMSE, had a Clinical Dementia Rating Scale of 0, and normal age-and education-adjusted scores on the Logical Memory delayed-recall test. All participants underwent a comprehensive medical and neurological evaluation to exclude major psychiatric or neurological disorders (see Methods).
Amyloid deposition is associated with increased hippocampal volume loss. We first examined whether smaller hippocampal volume at baseline and volume loss over time (or atrophy) was associated with neocortical amyloid deposition at baseline. Hippocampal volume, adjusted for intracranial volume, was determined by FreeSurfer 27 . Amyloid deposition was examined with PET using the Pittsburg compound-B (PiB) tracer expressed as the distribution volume ratio, with cerebellar gray as reference tissue 28 . Amyloid status was assessed using a cutoff of 1.20 (amyloid-positive, n = 61 subjects; amyloid-negative, n = 183; missing cases, n = 12) determined by a previous Gaussian mixture modeling approach 29 for the total sample, for a large cortical region-of-interest aggregate that included frontal, lateral, temporal and retrosplenial cortices.
Amyloid-positive individuals were significantly older and, as expected, were more likely to be APOE-ε 4 carriers compared to amyloid-negative individuals. No differences were found for sex, education, MMSE or memory scores. Even though amyloid-positive individuals showed lower adjusted hippocampal volumes at baseline (Table 1) , after correcting for age, sex and education the regression analyses showed no relationship between hippocampal volume and amyloid status at baseline (left hippocampus: β = -85.58, t 239 = -1.35, P = 0.18; 95% confidence interval (CI): -210.88, 39.72; right hippocampus: β = -86.85, t 239 = -1.54, P = 0.13; 95% CI: -197.97, 24.27) .
Longitudinal analyses with linear mixed-effect models showed a steeper decline in hippocampal volume in amyloid-positive compared to amyloid-negative individuals over a 6-year followup period (right hippocampus: β = -25.25, t 206 = -2.49, P = 0.014; 95% CI: -45.26, -5.24; left hippocampus: β = -17.86, t 206 = -2.01, P = 0.046; 95% CI: -35.36, -0.35; 453 observations, n = 244). These findings corroborate previous findings from our group and are consistent with disease models suggesting that neurodegeneration occurs downstream of amyloid pathology 29 . We should note, however, that tissue volume measures can reflect multiple underlying pathologies contributing to neurodegeneration, of which neurofibrillary tangles are the most characteristic of AD. Entorhinal tau and hippocampal volume measured at the nearest time point correlated significantly (left: r = -0.43, right: r = -0.36; P < 0.001), suggesting that hippocampal volume may be a reasonable proxy for early tau pathology.
Lower hippocampal volume is associated with white matter abnormalities of HCB and UF at baseline. We examined whether there was a relationship between hippocampal volume at baseline with tract diffusivity at baseline. Tract diffusivity was expressed in four metrics: fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AxD) and radial diffusivity (RD), using DTI. Using robust regression analyses with age, education and sex as covariates, we observed associations between right and left hippocampal volume and right and left FA, MD and RD of the HCB (n = 256) respectively (Supplementary Table 1 and Supplementary  Fig. 2 ). Associations between hippocampal volume and diffusivity of the UF (n = 253) were only found for the right hemisphere. These results confirm an association between local volumetric measures and local structural tract properties. Because Braak neurofibrillary tangles at stage I-II (involvement of entorhinal cortices and hippocampal formation) were present in more than 80% of individuals aged 60 years and older 18, 30 , these associations are likely a reflection of age-related processes, including tau deposition. However, for determining the propagation of tau pathology potentially indicative of memory decline as part of preclinical AD, it will be important to look at tau accumulation in regions associated with later neurofibrillary tangle stages and, hence, the presence of tau lesions in limbic regions. The relationships that were specifically analyzed in this article are within the blue box. The green boxes hypothesize that hippocampal volume loss results from neuronal damage, partially due to early tau pathology in the medial temporal lobe (MTL). As tau PET was acquired later in the study and thus this information was not available at baseline, we could not examine the green boxes. The relationship between hippocampal volume and diffusivity of the HCB was analyzed using both baseline measures of hippocampal volume and change in hippocampal volume over time.
Hippocampal volume predicts change in diffusion over time of HCB, but not in UF.
In accordance with our model (Fig. 1 ), we next assessed the hypothesis that hippocampal volume would predict changes in HCB diffusivity over time, but not changes in UF diffusivity. To that end, we used a linear mixed-effects model to predict annual change in tract diffusivity, with baseline hippocampal volume as predictor. We also investigated whether diffusivity changes and hippocampal volume changes occur simultaneously. Age, education and sex were included as covariates. We report the statistics of the MD component, as this metric is most commonly associated with aging and the earliest episodic memory deficits 15 . Statistics for these and the other metrics can be found in Supplementary Figs. 3 and 4 and Supplementary Table 2 . Hippocampal volume at baseline predicted a change in HCB diffusivity in such a way that lower hippocampal volume at baseline was associated with more abnormal white matter diffusivity over time (higher MD, AxD, RD). These associations were only significant for the right side (for MD: left: β = -0.0006, t 128 = -0.82, P = 0.417; right: β = -0.002, t 128 = -2.26, P = 0.025; 386 observations; Fig. 2 and Supplementary Fig. 3 ). Hippocampal volume did not predict changes in UF diffusivity over time (for MD: left: β = 0.001, t 123 = 0.42, P = 0.675; right: β = 0.0005, t 123 = 1.07, P = 0.283; 379 observations; Fig. 2 and Supplementary Table 2 ). Similar relationships were observed when investigating the association between change in hippocampal volume with change in HCB or UF diffusivity ( Supplementary Fig. 4 ). Right hippocampal volume change predicted a change in right HCB MD, but no associations were found for the left hemisphere (for MD: left: β = -0.029, t 128 = -1.06, P = 0.29; right: β = -0.037, t 128 = -2.19, P = 0.03; 386 observations). No associations were found between change in hippocampal volume and change in UF diffusivity (for MD: left: β = -0.041, t 123 = -0.48, P = 0.63; right: β = 0.004, t 123 = 0.50, P = 0.62; 379 observations; Supplementary Table 2 ).
To establish directionality, we also modeled reverse associations, investigating whether baseline or change in white matter diffusivity of these tracts predicted hippocampal volumes changes over time. Neither baseline nor change in HCB or UF diffusivity (left and right) predicted changes in hippocampal volume over time ( Supplementary Table 3 ).
These results support the hypothesis that hippocampal volume specifically is associated with white matter abnormalities of the HCB and not another nearby tract. Notably, we only found associations for the right hemisphere, even though right hippocampal volume was larger than the left (mean difference = 106.11, paired t test t = -6.75, P < 0.001). Furthermore, we were able to show directionality in these associations.
Hippocampal cingulum diffusivity selectively predicts accumulation of tau pathology in the connected PCC in amyloid-positive individuals.
Our previous analyses suggested that hippocampal neurodegenerative processes are associated with structural abnormalities of nearby tracts. However, the question remains whether neurodegenerative-associated connectivity loss predicts increased accumulation in a region at the anatomic terminus of the HCB. To that end, the linear mixed-effects models included annual tau accumulation in the PCC as the outcome measure and white matter diffusivity at baseline as the predictor. Tau accumulation was measured beginning, on average, 3.01 years (± 0.96) after baseline MRI measurement (n = 141), with an average follow-up (n = 71) duration of 2.24 ± 0.49 years. In all models, tau binding was expressed as annual increase (from baseline MRI) in regional binding (with cerebellar gray as reference and corrected for partial volume effects) 12 . All models were corrected for age, education and sex. The baseline FTP-subsample (n = 141) did not differ from the original baseline sample (n = 256) with respect to age (Welch's t test, t 279.69 = -0.38, P = 0.70), education (Welch's t test, t 289.6 = 0.92, P = 0.36), sex (chisquared test, χ 2 = 0.003, P = 0.95), MMSE scores (Welch's t test, t 317.25 = 1.23, P = 0.22) or PiB-PET levels (Welch's t test, t 301.36 = -0.26, P = 0.79). PCC tau binding at baseline was not different between individuals with only baseline data versus those with follow-up data (left: Welch's t test, t 124.76 = -0.45, P = 0.65; right: Welch's t test, t 104.9 = -1.25, P = 0.22).
Diffusion values (MD, AxD, RD) at baseline of the HCB predicted annual changes in PCC tau for the right hemisphere (MD: β = 0.002, t 69 = 2.55, P = 0.012, n = 212 observations), not the left (MD: β = -0.001, t 69 = -0.93, P = 0.356; Fig. 3 and Supplementary  Table 4 ). These effects were not changed when we included baseline Mean and s.d. (or n and % for dichotomous variables) are provided. Two-sided Welch's t tests were used to calculate group differences for the continuous variables, and χ 2 tests were used for comparing proportions across both groups. Hippocampal volumes are adjusted for intracranial volume. DVR, distribution volume ratio; SUVr, standardized uptake value ratio.*P < 0.05; **P < 0.01; ***P < 0.001. # Tau binding levels are from the first tau PET measurement (103 amyloid-negative; 36 amyloid-positive individuals).^Missing data for APOE ε 4 status for amyloid-negative (n = 28) and amyloid-positive (n = 7) individuals. $ MD measures were multiplied by 1,000. Axial and radial diffusivity values correlated with the MD measurements at r = 0.96 and r = 0.99, respectively.
hippocampal volume in the model (right: for MD: β = 0.002, t 69 = 2.47, P = 0.016; left: for MD: β = -0.001, t 69 = -0.96, P = 0.341). Even though hippocampal volume at baseline by itself did not predict PCC tau accumulation over time (right side: β = -0.00001, t 68 = -0.83, P = 0.409; left: β = -0.00001, t 68 = -0.23, P = 0.821), these results provide evidence that HCB diffusivity has a more proximal relationship to PCC tau accumulation over time than does hippocampal volume. Baseline diffusion values of the UF were not associated with accumulation of tau in the PCC (right: for MD: β = 0.001, t 68 = 0.61, P = 0.544; left: for MD: β = 0.001, t 68 = 1.33, P = 0.186; Fig. 3 and Supplementary Table 4 ). These analyses suggest that tau pathology associated with reduced hippocampal volume affects specific tracts and that more abnormal diffusivity in those tracts is associated with increased tau accumulation in a downstream-connected region. To show that this tau accumulation is specific to the PCC, we ran the same models but with tau binding in the IT cortex as the outcome. As shown in Fig. 3 , HCB diffusivity values at baseline did not predict tau accumulation in the IT cortex (right: for MD: β = 0.0004, t 69 = 0.65, P = 0.517; left: for MD: β = -0.0004, t 69 = -0.45, P = 0.657; Supplementary Table 5 ). As tau PET data was acquired later in the study, we were not able to investigate the opposite direction, i.e., whether accumulation of PCC tau also has detrimental effects on HCB diffusivity.
We next investigated the role of neocortical amyloid deposition in the propagation of tau via white matter connectivity. Amyloid status was assessed using the cutoff 1.20 (n = 2 missing for participants who underwent FTP-PET). Baseline amyloid status had no direct effect on tau accumulation in the PCC (left: β = 0.01, t 69 = 0.58, P = 0.57; right: β = -0.028, t 69 = 1.74, P = 0.086; 210 observations). We then investigated a three-way interaction, baseline amyloid × baseline HCB diffusivity × time, in predicting PCC tau accumulation over time. The three-way interaction (210 observations) was significant for right-sided associations (FA, MD and RD) and not for left-sided associations (right: for MD: β = 0.004, t 67 = 2.58, P = 0.012; left: for MD: β = 0.001, t 67 = 0.29, P = 0.775; Supplementary Table 6 and Supplementary Fig. 5 ). The associations between baseline right HCB diffusivity and tau accumulation in the right PCC were only found in amyloid-positive individuals (amyloid-positive (n = 36), for MD: β = 0.005, t 20 = 3.35, P = 0.003; amyloid-negative (n = 103), for MD: β = 0.001, t 47 = 1.36, P = 0.179; Fig. 3 ).
Together, these results suggest that the mechanism underlying tau propagation from the hippocampus to the PCC is related to reduced diffusivity of a connected white matter fiber bundle, the HCB, and not via a proximate connection. The strength of the association between HCB diffusivity and PCC tau is stronger under higher levels of amyloid pathology.
Memory-tract diffusivity associations are driven by tau pathology.
Previous studies have shown that tau pathology outside the medial temporal lobe is closely linked with changes in cognition 12, 14 . Baseline FTP-PET data were classified into two groups: participants with low (n = 93) or high (n = 48) PCC tau binding. The cutoff, a standardized uptake value ratio of 1.28, was determined with a Gaussian mixture modeling approach ( Supplementary Fig. 6 ). Running these models with PCC tau binding as a continuous measure led to similar results. Memory performance scores were based on factor scores from the total HABS cohort. We performed linear mixed-effects models with baseline HCB diffusivity as the predictor and annual changes in memory performance as the outcome. In the second step, we examined the interaction between HCB diffusivity by PCC tau status in predicting memory changes, hypothesizing that memory decline associated with increased HCB diffusivity would be stronger in participants with higher tau levels. As in the previous analyses, tau in the IT cortex was also used as a control region for PCC tau (for the Gaussian mixture model defining the cutoff for IT tau (standardized uptake value ratio = 1.73, partial volume-corrected; see Supplementary Fig. 6 ). In all models, age, education and sex were included as covariates. To investigate cognitive domain specificity, control analyses were performed with an executive composite score based on factor scores from the total cohort.
Left and right HCB diffusivity (lower FA, higher MD and RD) at baseline predicted memory decline (right: for MD: β = -0.002, t 906 = -2.70, P = 0.007; left: for MD: β = -0.003, t 906 = -2.56, P = 0.011; n = 1,167 observations), not executive performance decline (right: for MD: β = -0.0004, t 896 = -0.55, P = 0.58; left: for MD: β = -0.0008, t 896 = -0.80, P = 0.42; n = 1,157 observations). The three-way interaction, HCB diffusivity × PCC tau status × time, on memory performance was significant for the right HCB (MD, AxD and RD) and not the left HCB (right: MD: β = -0.006, t 566 = -2.43, P = 0.015; left: MD: β = 0.002, t 566 = 0.73, P = 0.466; 714 observations, n = 141 participants; Supplementary Table 7 and Supplementary Fig. 7 ). This interaction showed that participants with high PCC tau were driving the association between right HCB diffusivity and memory performance over time (high PCC tau (n = 48, 248 observations): MD: β = -0.006, t 195 = -3.20, P = 0.001; low PCC tau (n = 93, 466 observations): MD: β = -0.001, t 368 = -0.93, P = 0.352; Fig. 4 ). To show regional specificity, we ran another three-way interaction, HCB diffusivity × IT tau status × time, on memory performance and found no significant association for the right or left HCB (right MD: β = -0.005, t 566 = -1.44, P = 0.150; left: MD: β = 0.008, t 566 = 1.17, P = 0.241; 714 observations, n = 141; Supplementary Table 7 ). Furthermore, no significant three-way interactions were observed with executive function over time as the outcome measure (for PCC tau: right MD: β = -0.001, t 563 = 0.63, P = 0.53; left MD: β = 0.0004, t 563 = 0.15, P = 0.88; 711 observations, n = 141; for IT tau: right MD: β = 0.0001, t 563 = 0.03, P = 0.97; left MD: β = 0.002, t 563 = 0.28, P = 0.78; 711 observations, n = 141; Supplementary Table 8 ).
We then investigated whether, in the group with high PCC tau levels, the association between right HCB diffusivity and memory was larger in amyloid-positive compared to amyloid-negative individuals (three-way interaction for MD of right HCB: β = -0.009, t 193 = -2.36, P = 0.019; 248 observations, n = 48). Breaking this interaction down confirmed that amyloid-positive individuals were driving these effects (amyloid-positive individuals: n = 18, n = 95 observations: MD: β = -0.011, t 72 = -3.69, P = 0.0004; amyloidnegative individuals: n = 30, n = 153 observations: MD: β = -0.002, t 118 = -0.59, P = 0.556; Fig. 4 ).
Discussion
A defining feature of AD is the progressive accumulation of amyloid and tau pathology. Current disease models suggest a temporal trajectory in which amyloid pathology initiates a chain of events including the increases in amount and extent of tau pathology 31 . The question of how tau pathology propagates from one region to another is crucial for understanding the pathophysiological mechanisms of AD, but is also important for developing novel therapeutics. Potential mechanisms of tau propagation that have been suggested in histological and animal studies include connectivity, proximity, diffusion along axons and neural activity [5] [6] [7] [8] [9] .
In the present work, we provide in vivo evidence that amyloid pathology-a key determinant in the onset of AD 32 -accompanies the stronger association between structural alterations of the HCB and accumulation of tau pathology in the downstream PCC. By combining several established and innovative in vivo neuroimaging methods, we showed that accumulation of tau pathology in a downstream-connected region is specifically associated with properties of connections of that region and not with other proximate connections, such as the UF. While we recognize that current neuroimaging techniques do not have the resolution to understand the molecular mechanisms of tau propagation, these results are consistent with several animal studies and current disease models 9, 11, 33 , and they also establish a link to memory decline.
Propagation of tau has been investigated predominantly in animal studies. Several studies have shown a stereotypic increase in tau pathology in a time-dependent manner, both locally and distal to regions with synaptic connections [3] [4] [5] , involving axonal degeneration 3, 9 . Tau propagation has been observed from tau-infused rodent hippocampus to distal regions such as olfactory and retrosplenial cortices 3, 4, 33, 34 . These observations are consistent with our findings of downstream-increased PCC tau (including in the retrosplenial cortex) in relation to abnormalities of the connecting HCB, which in turn was associated with lower hippocampal volume at baseline. The fact that hippocampal volume was not directly associated with PCC tau accumulation suggests that changes in tract diffusivity may be an observation related to the underlying mechanisms mediating the spreading of tau 3, 6, 8 . The fact that these associations showed regional selectivity and were not related to diffusivity of another tract or tau in an adjacent region supports the idea that tau pathology propagates via connectivity 3 . Since the majority of these findings were found in MD, AxD and RD metrics, hippocampal tau pathology seems to induce disruption of both axons and myelin. Variations in the AxD and RD components need to be interpreted cautiously, as these inferences are largely based on animal studies 35 . Even though we corrected for partial volume effects, it is possible that hippocampal atrophy may have influenced our results. Future studies should therefore consider acquiring multishell sequences, such as NODDI, to increase the specificity of these findings. We did not find evidence for the reverse association (baseline HCB diffusivity predicting hippocampal volume changes over time), suggesting a biological ordering that fits with the spatiotemporal topography of tau pathology, in which the hippocampus is affected prior to a tract leaving the medial temporal lobe. We note that neurodegeneration is a slow process, and tau and neurodegeneration may be occurring in parallel, with different magnitudes. Tau propagation may be necessary but not sufficient for volume loss. Most of the animal studies also found no evidence for tau-induced neurodegeneration, but the animals were on average not very aged 3, 9, 36, 37 . As for retrograde associations, immunohistochemistry studies have shown evidence for both anterograde cell-to-cell propagation and combined anterograde and retrograde spread of tau to and from the hippocampus and mammillary nuclei, and inconsistencies between our results and these studies may be related to differences in spatial resolution inherent to the methodology.
To our knowledge, this is the first study suggesting that changes in tract diffusivity are likely related to the biological mechanisms underlying the association between hippocampal volume and PCC tau accumulation over time. The PCC is an important neuronal hub that displays extensive amyloid deposition in animal studies and human neuroimaging studies [38] [39] [40] and plays a crucial role in spatial learning and memory 41 . Animal studies have also suggested propagation from the entorhinal cortex to medial frontal regions or olfactory cortex, and thus this phenomenon is most likely not limited to the hippocampus-PCC connection. Since we investigated cognitively healthy older individuals, the variability in frontal tau binding was limited. Longer follow-ups or inclusion of early AD patients will allow extension of this model to other brain networks.
Abnormalities of the HCB have been associated with increased amyloid deposition 38, 42 . We found that amyloid is associated with an increased relationship between PCC tau and the HCB, suggesting that amyloid is a crucial part of the chain of events promoting tau spread 22 and specifically linked to tau-related memory decline. While the role of amyloid as a driving force for tau propagation to distal regions has been shown in in vitro and in vivo models 11, 33, 34 , the exact molecular mechanism underlying tau propagation and its facilitation by amyloid are still poorly understood 43 . Hyperphosphorylation 5,37,44 is one potential mechanism, as dephosphorylation in animal models has been shown to reduce tau propagation. Whether tau pathology in turn can exacerbate amyloid plaques is still under debate 11, 45 . We did not test this in our study, as variability in PiB-PET measures over time is low and requires longer follow-up.
These data do not preclude the possibility that other factors, or a combination of factors, induce tau propagation 10 . Animal studies have also provided evidence for functional spread, in which regions that fire synchronously and have higher metabolism are more vulnerable 4,6,8 . Khan et al. reported that tau pathology in the medial temporal lobe of APP/tau mice led to secondary functional changes in medial parietal regions 4 . Notably, neuronal networks with a high load of neurofibrillary tangles can remain functionally intact, suggesting that more downstream elements at the axonal or synaptic level may show tau-related defects 46 .
We note that all associations we observed were lateralized to the right. Some degree of asymmetry of tau is common in AD pathology 6 . A recent study showed bilateral tau pathology with a stronger involvement of the right hemisphere when comparing cognitively healthy with cognitively impaired individuals 47 . This lateralization may be related to disease stage, so that in cognitively healthy older individuals, tau accumulation in the left hemisphere has not yet crossed the detection threshold. However, it has been shown that asymmetries in amyloid and tau pathology occur and remain stable during disease progression 48, 49 . Alternatively, these right-sided associations may also be specific to the cognitive domain under investigation. Recent work indicates that amyloid-memory (verbal and visuospatial) associations are slightly more right lateralized 48 , and work from our group showed stronger right-side relationships between tau pathology and hypometabolic tempoparietal patterns in amyloid-positive individuals 50 . It is also possible that the rightsided effects reflect a selection bias. Left-sided pathology may induce more pronounced cognitive deficits, such as language problems, which would exclude such individuals from our study at baseline. Whether this lateralization is also seen in patients or is associated with other cognitive domains needs to be further examined.
The recent development of FTP-PET tracers allows us to measure and visualize tau pathology in vivo, but as they were recently introduced in the HABS cohort, we did not have this information available at baseline. Therefore, we started our cascade of events with hippocampal volume as a proxy of tau pathology. Hippocampal volume changes can also reflect amyloid deposition or various non-AD-related pathological processes, including Lewy bodies, vascular lesions, hippocampal sclerosis, TDP-43 inclusions and argyrophilic grain disease. Nonetheless, hippocampal atrophy is a common accompaniment to AD-related pathology, especially neurofibrillary degeneration 20 .
In summary, our findings suggest that amyloid contributes to increased spreading of tau via the HCB, confirming that amyloid is a crucial part of the chain of events leading to increased tau pathology and contributing to tau-related memory decline. Possible upstream molecular mechanisms enabling the spread of tau pathology or pathways by which amyloid may potentiate this spread have not been tested with our data and remain open questions. Nonetheless, these findings provide empirical foundations for future work on disease models and suggest that the extent of tau pathology spreading may be an interesting outcome measure for clinical trials 44 focused on removal of amyloid plaques in the earliest stages, as amyloid potentiates tau propagation.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0070-z.

Participants. Healthy older individuals from the Harvard Aging Brain Study who underwent 3 T MRI including diffusion tensor imaging (DTI) at baseline
were included in the present study (n = 256, mean age = 74.07 (s.d. = 6.21)). The Harvard Aging Brain Study is a longitudinal study on aging and AD 26 . Participants undergo annual neuropsychological testing and multiple imaging sessions. Participants were included if they had a global score of 0 on the Clinical Dementia Rating scale 51 , a Mini-Mental State Examination score ≥ 25 52 , and performed within education-adjusted norms on the Logical Memory delayed-recall test ( > 10 for ≥ 16 years of education, > 6 for 8-15 years of education and > 4 for < 8 years of education). All participants underwent at least one comprehensive medical and neurological evaluation and had no major psychiatric or neurological disorders. Presence of clinical depression (Geriatric Depression Scale below 11/20 53 ) or other psychiatric illnesses, history of alcoholism, drug abuse, head trauma, or a family history of autosomal dominant Alzheimer's disease were exclusion criteria. All behavioral and neuroimaging experiments were performed during daytime. Study protocols were approved by the Partners Human Research Committee at Massachusetts General Hospital, and all participants provided written informed consent. We complied with all ethical regulations.
Structural MRI. All imaging was performed at the Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging on a 3 T imaging system (TIM Trio; Siemens) with a 12-channel phased-array head coil. Head motion was controlled with a foam pillow and extendable padded head clamps.
The protocol included a structural T1-weighted volumetric magnetizationprepared rapid-acquisition gradient-echo (MPRAGE) sequence (repetition time (TR) = 2,300 ms, echo time (TE) = 2.95 ms, and inversion time = 900 ms, flip angle = 9°; and 1.05 × 1.05 × 1.2 mm resolution). Diffusion-weighted images were acquired with a single-shot spin echoplanar imaging sequence (TR = 8,040 ms, TE = 84 ms, flip angle = 90°, field of view = 256 × 256 × 128, voxel size = 2 mm isotropic, 30 isotropically distributed diffusion-sensitizing gradients with a b-value of 700 s/mm 2 and 5 nondiffusion weighted images (b = 0 s/mm 2 )). Participants were scanned at baseline (n = 256) and a second time after an average of 2.82 years (n = 134, median follow-up 2.62 years (IQR, 2.51-2.85)).
The diffusion MRI data were processed with ExploreDTI version 4.8.6 54 . Data preprocessing included correction of subject motion, eddy current distortion correction, incorporating the B-matrix rotation to preserve the diffusion gradient orientation information correctly, echoplanar imaging susceptibility correction based on each individual's baseline skull-stripped anatomical image, and tensor estimation using the robust nonlinear least-squares Restore algorithm. Tracks of interest from the JHU Mori atlas template 55 were warped to each subject's native space using affine and diffeomorphic elastic registration based on 'elastix' 56 . Fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AxD) and radial diffusivity (RD) values were extracted from the tracts of interests after thresholding FA > 0.20 to exclude partial volume effects. Additionally, tract size was included in our statistical models. Partial volume effects vary with the size of the tract, and simulations have shown that this approach can account partially for this contamination 57 . The tract of interest was the hippocampal cingulum bundle (HCB), and the uncinate fasciculus (UF) was chosen as control tract. In three individuals, the UF could not be estimated accurately due to signal dropout, and these individuals were discarded for analyses including this tract. The bootstrapped (n = 500) intraclass correlation coefficient (ICC), adapted for longitudinal data 58 , demonstrated adequate measurement reliability over time. For the HCB, the ICC was 0.63, 0.66, 0.65 and 0.62 for the MD, FA, AxD and RD components, respectively. For the UF, the ICC was 0.81, 0.56, 0.74 and 0.84 for the MD, FA, AxD and RD components, respectively. T1-weighted images were processed in FreeSurfer (FS) version 5.1 using the software package's default, automated reconstruction protocol, as described previously 27, 59 . Briefly, each T1-weighted image was subjected to an automated segmentation process involving intensity normalization, skull stripping, segregating left and right hemispheres, removing brainstem and cerebellum, correcting topology defects, defining the borders between gray/white matter and gray/cerebrospinal fluid, and parcellating cortical and subcortical areas. Using FreeSurfer's native visualization toolbox, tkmedit, we visually inspected and, if necessary, edited each image for over-or underestimation of the gray/white matter boundaries and to identify brain areas erroneously excluded during skull stripping.
Participants received T1-weighted scans at baseline (n = 256), a second time after, on average, 2.82 years (n = 157) and a third time after, on average, 5.08 years from baseline (n = 53). The total median follow-up was 2.84 years (IQR, 2.61-4.64). The ICC for hippocampal volume measurements over time was 0.88.
Hippocampal volume was adjusted for the estimated intracranial volume (eTIV) using the following equation 29 :
Adjusted hippocampal volume raw hippocampal volume (eTIV Mean eTIV)
where b indicates the regression coefficient when hippocampal volume is regressed against eTIV.
PiB-positron emission tomography. Pittsburgh compound B-positron emission tomography (PiB-PET) was performed at the Massachusetts General Hospital PET facility. Carbon 11-PiB was synthesized using a previously published protocol, and imaging was performed at baseline using a PET system (ECAT EXACT HR+ ; Siemens). 11 C PiB PET was acquired with an 8.5-15 mCi bolus injection followed immediately by a 60-min dynamic acquisition in 69 frames (12 frames × 15 s, 57 frames × 60 s). 11 C PiB PET data were expressed as the distribution volume ratio (DVR) with cerebellar gray as reference tissue, using the Logan graphical method applied to data from 40 to 60 min after injection 28 . PiB retention was assessed using a large cortical ROI aggregate that included frontal, lateral, temporal and retrosplenial cortices (FLR) as described previously 60, 61 . Amyloid status was ascertained by a previously determined cutoff value based on Gaussian mixture modeling approach (cutoff value = 1.20) 29 . Based on this cutoff, 183 individuals were classified as amyloid-negative and 61 as amyloid-positive at baseline (for 12 cases there was no baseline PiB-PET measurement). The global PiB-DVR was 1.109 (IQR, 1.063-1.202); the median baseline PiB imaging delay from the first neuropsychological assessment was 0.35 years (IQR, 0.24-0.49 years) and the median delay from the first MRI scan was 0.003 years (IQR, -0.20 to 0.12 years).
Flortaucipir (FTP)-PET. Fluorine 18-FTP was prepared at MGH with a radiochemical yield of 14 ± 3% and specific activity of 216 ± 60 GBq/μ mol at the end of synthesis (60 min), and validated for human use 62 . PET images were acquired on a Siemens/CTI (Knoxville, TN) ECAT HR+ scanner (3D mode; 63 image planes; 15.2-cm axial field of view; 5.6-mm transaxial resolution and 2.4mm slice interval). 18 F FTP was acquired 80-100 min after a 9.0-11.0 mCi bolus injection in four 5-min frames. PET data were reconstructed and attenuation corrected, and each frame was evaluated to verify adequate count statistics and the absence of head motion. To evaluate the anatomy of cortical FTP binding, each individual PET dataset was rigidly coregistered to the subject's MPRAGE data using SPM8 (Welcome Department of Cognitive Neurology, Function Imaging Laboratory, London). FreeSurfer ROIs defined by MR as described above were transformed into the PET native space. PET data were partial volume corrected using the geometrical transfer matrix method as implemented in FS 63 . 18 F FTP specific binding was expressed in FS ROIs, the PCC (FS labels the posterior cingulate/retrosplenial cortex as isthmus) and the IT cortex, as the standardized uptake value ratio (SUVr) using FreeSurfer's cerebellar gray ROI as reference. IT and entorhinal tau have so far been investigated more closely than PCC in older individuals. Zero-order Pearson's product-moment correlation coefficients show similar behavior across these measures (r = 0.58, P < 0.001 for PCC and IT and r = 0.45 and P < 0.001 for PCC and entorhinal tau). The ICC values showed adequate reliability over time (IT tau ICC = 0.86 and PCC tau ICC = 0.77).
As the FTP was only recently developed, FTP-PET was introduced later in the HABS study, on average 3.33 ± 0.77 years after the first neuropsychological assessment, 3.01 ± 0.96 years after the first MRI scan and 2.99 ± 0.83 years after the PiB-PET scan. As of the writing of this manuscript, 141 individuals had received a first FTP-PET scan and 71 individuals had been followed up after (on average) 2.24 years from their first tau PET scan. The median follow-up time for tau-PET was 2.16 years (IQR: 1.95-2.53).
Cognitive performance.
A memory and an executive function composite score were created based on a factor analysis from the entire HABS cohort (n = 284). The memory composite (with factor loading weights between parentheses) included the z-score transformations of the delayed recall scores of the 6-Trial Selective Reminding test 64 (0.739), free recall of the Free and Cued Selective Reminding Test (0.605) and delayed recall of the Logical Memory Test 65 (0.534). Memory was evaluated annually in HABS and therefore we included 1,167 evaluations (n = 256 at baseline, n = 246 at year 1, n = 233 at year 2, n = 194 at year 3, n = 157 at year 4 and n = 81 at year 5). The executive function composite included the z-score transformations of the Trail Making Test form B -A 66 (0.666), the Letter Number Sequencing test 67 (0.533) and the phonemic fluency FAS test 68 (0.622). Executive function was also evaluated annually and, at the time of the analyses, 1,157 observations were included (10 participants did not yet had scores for followup timepoint 5). The median follow-up duration was 4.05 years (IQR: 2.91-4.96 years). Experimenters collecting MRI or behavioral data were blind to amyloid status or level of tau binding, and experimenters collecting PET data were blind to the behavioral data and MRI results.
Statistical analyses. Statistical analyses were performed using statistical software (R version 3.3.0; http://www.r-project.org/). All analyses were done during January 2016 through May 2017. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 22, 29 .
Group characteristics are represented as medians and interquartile ranges. Differences between amyloid-positive and -negative individuals were tested with the Welch's two-sample t test to account for unequal variances or with the χ 2 test.
Baseline associations between adjusted hippocampal volume and amyloid status or white matter tract diffusivity (diffusion metrics) were investigated using linear robust regression methods with the Huber-M estimator. Robust regression is a more conservative test than linear least-square regression methods, as the resulting models are stable against outliers, which were present in the baseline absolute diffusion data.
Longitudinal analyses were performed with a stepwise hypotheses-driven linear mixed-effects (LME) modeling approach using the maximum likelihood estimation, containing a fixed effect for the predictor of interest, a random intercept for each subject and random slope for time (number of years between baseline and follow-up). For all LME models, we compared the Akaike Information Criteria between models with either a random intercept and random slope or a random intercept alone, using the log-likelihood ratio test, and chose the most parsimonious model. To control for longitudinal changes in voxel selection of tracts, we included analytic weights in the LME models examining diffusion values and weighing the error variance inversely by the tract size 69 . In all LME models, age, sex and education and their interaction with time were included as covariates if P < 0.10 (using the Wald t statistic).
To further examine the hypothesized relationships ( Fig. 1) , we performed several LME models. We provide the formula for the most complex model (with three-way interactions): where Var(ε ij ) = σ 2 /tract-size i , Var(b 1i ) = τ 2 1 , Var(b 7i ) = τ 2 7 and Cov(b 1i , b 7i ) = ρ × τ 1 × τ 7 . Outcome is the outcome variable measured over time; Age i , Education i , Sex i indicate age, education or sex at baseline testing session (i); Predictor A/B: variables of interest depending on the investigated model; Time ij is the time at testing session, relative to baseline testing session; b 1i is the random intercept for each subject; b si is the random slope for each subject (s); τ 2 1 is the variance of the residuals of the random intercept; and τ 2 6 is the variance of the residuals of predicting the random slope.
We first investigated differences in annual change in hippocampal volume between amyloid-positive and amyloid-negative individuals. The second models estimated mean annual change in each DTI metric in each tract predicted by baseline hippocampal volume and its interaction with time. To explore directionality, we also estimated mean annual change in adjusted hippocampal volume predicted by diffusivity of the tracts of interest.
In the next step, we estimated mean annual change in PCC tau predicted by tract diffusivity over time. The time variable reflects annual change in PCC tau since baseline MRI measurements (to check the robustness of our models, we also ran these models with the first tau measurement as baseline and also within a complete-case design (n = 71); these LMEs provided similar results). The same model was performed with a control tau region, the IT cortex, to establish regional specificity of the findings.
In the fourth step, we examined whether the change in tau predicted by HCB diffusivity was different for amyloid-positive versus amyloid-negative individuals by adding a three-way interaction in the model (HCB diffusivity at baseline × amyloid status × time).
In the final step, we investigated associations with annual changes in memory performance. First, we investigated whether HCB diffusivity predicted memory performance over time. Associations with executive functioning were investigated as control cognitive measure. Next, we added the interaction with PCC tau binding. The same analyses were performed with IT tau binding as control region.
To ease interpretation and allow us to break down the model, PCC/IT tau binding was dichotomized in low-versus-high PCC/IT tau load, determined with a Gaussian mixture modeling approach on the baseline data. This approach has been employed previously to classify individuals based on amyloid burden 70 or overall tau burden 71 . This method is preferred since it is data-driven. Multiple Gaussian distributions were fit to the data (1-5 distributions or mixtures, allowing for either equal or unequal variances), and the optimal model was selected by evaluating the Bayesian information criterion, which penalizes models with more parameters) and a bootstrapped (n = 5,000) sequential likelihood ratio test. The optimal model consisted of two distributions of unequal variance. The probability threshold for belonging to either the low-or high-tau group was set at 50%, which corresponded to a value of 1.28 for the PCC.
After running the LME with the three-way interaction baseline HCB diffusivity × PCC tau status × time, we ran a final model within the group with high PCC tau levels, containing the three-way interaction HCB diffusivity × amyloid status × time. Residual plots and QQ plots were examined for all models. All P values were two-sided, and no correction for multiple comparisons was performed (for each analyses, we performed four models for each diffusion metric; for diffusion-hippocampal volume cross-sectional and longitudinal associations: four comparisons were performed for the tract of interest and four for the control tract per side and per diffusion metric; for the association between tau and diffusion, a total of three comparisons were performed for the tract of interest and control region per side and per diffusion metric; for the cognitive analyses, a total of three comparisons were performed per cognitive measure, per side and per diffusion metric). 
Data exclusions
Describe any data exclusions. We excluded three data points for DTI measures of the uncinate fasciculus due to poor data (signal loss in the region of interest). This has been described on page 29 Missing data on amyloid status was also reported on page 7. Missing data on gentoyping for APOE is provided in Table1. Missing data for the longitudinal data is reported in the online methods section.
Replication
Describe whether the experimental findings were reliably reproduced.
No formal replication was done. However, the absolute diffusivities (AxD, RaD and MD) correlated highly, indicating that they measure a similar underlying process. Results for the these diffusivities were similar across the various analyses.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. N/A. No randomization was used. This was a cohort study.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis. N/A. However, experimenters collecting MRI or behavioral data were blind to amyloid status or level of tau binding and experimenters collecting PET data were blind to the behavioral data and MRI results. 
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Batch scripts were written in Matlab for the PET and MRI analyses (making use of FreeSurfer, SPM, ExploreDTI), this is reported on page 28 for DTI, page 29 last paragraph for MRI analyses, and page 30-31 for PET data. Data analyses was done in R as described on page 33
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No unique materials were used
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). 7. Normalization a. If data were normalized/standardized, describe the approach(es).
T1 data was intensity normalized using FreeSurfer's mri_normalize script (page 29) DTI data was corrected for echo-planar imaging susceptibility by applying an affine registration to the skull-stripped T1 image of FreeSurfer (this steps includes B-matrix rotation to preserve correct diffusion gradient rotation) See page 28 b. Describe the template used for normalization/transformation. All data was kept in subject-specific space, no templates were used. Note that for FreeSurfer, volumes are defined in several steps during which a high-dimensional non-linear registration is done to the MNI305 template to increase the accuracy of the segmentation and to facilitate the segmentation and tissueprobability assessment for region labeling. Volumes of the hippocampus are ultimately extracted from a subject-specific subcortical volumetric atlas (aseg) in 1mm isotropic subject-space. For the diffusion analyses, we used the JHU Mori atlas template for tract labeling, but tracts of interests were warped on each subject's data to not affect the gradient orientation. These tracts of interests were warped using diffeomorphic registration methods (see page [28] [29] 8. Describe your procedure for artifact and structured noise removal.
The standard preprocessing pipeline of FreeSurfer incorporates motion correction, intensity correction and skull-stripping (page [29] [30] . Diffusion data was corrected for eddy-current distortions, subject motion and echo-planar imaging susceptibility. Additionally, to correct for partial volume effects, images were thresholded at a FA-value of 0.20 (during the statistical analyses, additional correction was done by correcting for tract size). Motion correction, eddy current correction and handling of outliers was done with the REKINDLE robust non-linear least-squares estimation method. The correction for echo-planar imaging susceptibility was performed by applying an affine registration to the skull-stripped T1 image (including B-matrix rotation to preserve correct diffusion gradient rotation) (see page 28-29).
9. Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
NA, no functional MRI data was included
Statistical modeling & inference 10 . Define your model type and settings. All statistical analyses were done in R, not in the imaging software packages. Subject-specific values were extracted from predefined ROIs and group analyses were performed in R. We have performed regression analyses (robust regressions and mixed effects models for longitudinal data). See page 33-36 11 . Specify the precise effect tested. Associations between amyloid status and hippocampal volume were determined cross-sectionally and longitudinally. Associations between hippocampal volume and tract integrity were assessed cross-sectionally and longitudinally. No ANOVA or factorial designs were used, but robust regressions and mixed effects models for longitudinal analyses were performed. See page 33-36 a. Specify whether analysis is whole brain or ROI-based. ROI-based in which a limited set of ROIs (1 for structural data (hippocampus) and 2 for diffusion data (hippocampal cingulum bundle and uncinate fasciculus)) were chosen based on the hypotheses and model (figure 1, page 6; the rationale behind this model and these ROIs is provided on page 4-5 )
b. If ROI-based, describe how anatomical locations were determined.
All ROIs were chosen based on the model in figure 1 . FreeSurfer: a subject-independent probabilistic atlas (hand labeled atlas by neuroanatomists on a training set) provides subjectspecific measured values. Subject-specific segmentations of the hippocampus are based on these probabilities and on the white and pial surfaces. Hippocampal volumes, corrected for intracranial volume, were used in the analyses. Page 30 For diffusion data: masks of the tracts were based on the Johns Hopkins University Mori atlas. Tracts in this atlas were based on fiber orientations and hand segmentations on diffusion images. The atlas and tracts were registered to each subject using diffeomorphic methods. No statistical adjustments were done as the analyses were planned in the hypothesized model (this is indicated on page 36). We controlled these analyses by including control regions for the tract analyses (uncinate fasciculus), the tau analyses (inferior temporal cortex was control region) and the cognitive domain (executive function as control domain) as explained on page 4-5. Furthermore, the diffusion analyses were complementary as shown in the consistency in all the diffusion metrics outcomes (the chance for a type I error decreases when tests are positively correlated; the absolute diffusivity metrics are highly positively correlated, see correlations below 
